# EDGAR Filing Document

**Accession Number:** 0001829667
**File Stem:** 0001213900-23-015052
**Filing Date:** 2023-2
**Character Count:** 3737
**Document Hash:** 488b87547cf00a6cab92df7ba1b2e1ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-015052.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001213900-23-015052

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230228

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regencell Bioscience Holdings Ltd
- **CENTRAL INDEX KEY:** 0001829667
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40617
- **FILM NUMBER:** 23678908

**BUSINESS ADDRESS:**
- **STREET 1:** 11/F FIRST COMMERCIAL BUILDING
- **STREET 2:** 33-35 LEIGHTON ROAD, CAUSEWAY BAY
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077
- **BUSINESS PHONE:** 852 2155 0823

**MAIL ADDRESS:**
- **STREET 1:** 11/F FIRST COMMERCIAL BUILDING
- **STREET 2:** 33-35 LEIGHTON ROAD, CAUSEWAY BAY
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2023**

**Commission File Number: 001-40617**

**Regencell Bioscience Holdings Limited**

**11/F First Commercial Building**

**33-35 Leighton Road**

**Causeway Bay, Hong Kong**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Appointment of Chief Business Officer**

Regencell Bioscience Holdings Limited, a company incorporated under the laws of the Cayman Islands (the "Company" or "Regencell"), promoted Yat-Pui Au ("Mr. Au") from senior vice president of the Company to chief business officer of the Company, effective February 1, 2023.

"We are delighted to promote Yat-Pui to the role of chief business officer. Yat-Pui is an accomplished professional in strategic management and business operations, with a track record in the physical security and property management sectors industry. We believe Yat-Pui will continue to contribute to our growth," said Yat-Gai Au, the chief executive officer and chairman of the board of directors of the Company.

Mr. Au has more than 24 year experience in strategic management and business operations. He joined Regencell in October 2021. Prior to Regencell, he worked at various leading roles in the physical security and property management sectors, where he implemented digital and cloud-based CRM solutions, completed major technology projects for governmental/institutional/private sectors, and streamlined business operations across marketing, finance, IT, human resources and operations departments. Mr. Au started his career as a consultant analyst for Computer Sciences Corporation for IT/MIS integrations and deployment. Mr. Au obtained his bachelor's degree in legal studies from University of California, Berkeley. Mr. Au is the brother of Yat-Gai Au, the chief executive officer and chairman of the board of directors of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 28, 2023

---

| | |
|:---|:---|
| **Regencell Bioscience Holdings Limited** | **Regencell Bioscience Holdings Limited** |
| By: | /s/ Yat-Gai Au |
| Name: | Yat-Gai Au |
| Title: | Chief Executive Officer and Chairman of the Board of Directors |

---